Know Cancer

or
forgot password

An Academic Prospective Single-arm Phase II Clinical Trial for Evaluation of Advanced Functional Neuroimaging Techniques and Molecular Markers in the Course of Anti-angiogenic Therapies in Malignant Gliomas


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Recurrent Malignant Glioma

Thank you

Trial Information

An Academic Prospective Single-arm Phase II Clinical Trial for Evaluation of Advanced Functional Neuroimaging Techniques and Molecular Markers in the Course of Anti-angiogenic Therapies in Malignant Gliomas


Inclusion Criteria:



1. Patients present with a first or second tumor recurrence / progression of a
histological confirmed supratentorial malignant glioma WHO Grade III-IV
(Classification following WHO criteria).

2. Patients with surgical resection of tumor recurrence / progression: Following
standard therapy(first recurrence) or standard therapy / second line chemotherapy
(second recurrence, excepting antiangiogenic approaches) patients must have evidence
of further tumor progression measured by standard MRI sequences (MacDonald criteria).
If possible, patients may have prior surgical resection of the tumor progression and
will be eligible if the following conditions apply:

- Patients must have recovered from the effects of surgery

- To adequately asses the malignant glioma before surgery and the extent of
residual disease postoperatively, two MRIs scans have to be performed:

- A first standard MRI scan has to be done within 1 week before surgery to
document a progressed or recurrent malignant glioma.

- A second standard / functional MRI scan has to be done between 24 and 48 hours
after surgery to document the postoperative malignant glioma (Baseline MRI
scan).

- FET- / FLT-PET scans have to be done within 2 weeks after surgery to document
the postoperative malignant glioma (Baseline PET scans).

Patients without surgical resection of the tumor recurrence / progression: Patients
must have evidence of tumor progression measured by standard MRI sequences (MacDonald
criteria).

- Additional functional MRI sequences have to be done within 1 week prior to study
enrollment.

- FET- / FLT-PET scans have to be done within 2 weeks after surgery to document
the postoperative malignant glioma (Baseline PET scans).

3. Resolution of all acute toxic effects of prior therapy to grade ≤ 1 (except alopecia)

4. Patients must have an ECOG performance status of 0-2

5. Patients must be ≥ 18 years and ≤ 80 years of age, with a life expectancy of greater
than 8 weeks

6. Patients must have adequate organ function as defined by the following criteria:

Bone Marrow Reserve

- Platelets ≥ 75.000/μL

- Absolute Neutrophil Count ≥ 1500/μL

- Hemoglobin ≥ 10.0 g/dL Blood Coagulation

- aPTT ≤ 1.5 times upper limit of normal (ULN) Hepatic Function

- ASAT and ALAT ≤ 2.5 times ULN

- ALP ≤ 2.5 times ULN

- Total SERUM Bilirubin < 1.5 times ULN Renal Function

- SERUM Creatinine ≤ 1.5 times ULN Metabolism

- SERUM Albumin ≥ 3.0 g/dL All tests must be performed ≤ 3 days prior to study
enrollment. Eligibility for hemoglobin count may be reached by transfusion.

7. Signed and dated informed consent document by the patient, indicating that the
patient has been informed of all the pertinent aspects of the trial prior to study
enrollment.

8. Willingness and ability of the patient to comply with scheduled visits, treatment
plans, laboratory tests, and other study procedures.

Exclusion Criteria:

9. The patient is active participant in another clinical trial, which investigates
substances with antiangiogenic effectiveness

10. Exclusion of patients in the event of

- surgery of a recurrent / progressed malignant glioma within 2 weeks prior to
study enrollment

- chemotherapy (Standard therapy o Second Line Chemotherapy) within 2 weeks prior
to study enrollment

- radiation therapy (Standard therapy) within4 weeks to study enrollment

- evidence in baseline MRI of intratumoral or peritumoral hemorrhage deemed
clinically significant by the treating physician (area of hemorrhage > 25% of
tumor area)

11. Significant Co-Morbidities within 12 months prior to study enrollment

- myocardial infarction, severe/unstable angina pectoris, coronary/peripheral
artery bypass graft, congestive heart failure

- cerebrovascular accident including transient ischemic attack

12. Significant Co-Morbidities at Baseline Evaluation

- Hypertension that cannot be controlled by medications (>150/100 mmHg despite
optimal medical therapy)

- Pulmonary embolism within 4 weeks before study enrollment

- A known HIV (human immunodeficiency virus) or Hepatitis B/C infection or severe
acute infection

13. Anticoagulation: Current treatment with therapeutic doses of Marcoumar / Sintrom
excluding thrombosis prophylaxis with low dose Heparin

14. Pregnancy, Breastfeeding and Non-Contraception

- Female patients who are pregnant or nursing

- Patients who are sexually active and unwilling or unable to use a medically
acceptable method of contraception during the trial

15. Evidence of increased intracranial pressure

- midline shift > 5 mm

- headache, distinct nausea and vomiting

16. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that would impart excess risk associated with study participation or
study drug administration, or which would make the patient inappropriate for entry
into this study. The decision to enroll the patient in this study is in the judgment
of the investigator.

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

To determine the objective tumor response criteria (RR, ORR, ORD) assessed by Standard MRI and FET-/FLT-PET during Avastin / Irinotecan chemotherapy.

Outcome Time Frame:

three years

Safety Issue:

No

Principal Investigator

Guenther Stockhammer, MD, Prof.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Department for Neurology, Medical University Innsbruck

Authority:

Austria: Austrian Federal Office for Safety in Health Care

Study ID:

EUDRACT-Nr: 2009-015036-15

NCT ID:

NCT01144988

Start Date:

March 2010

Completion Date:

March 2013

Related Keywords:

  • Recurrent Malignant Glioma
  • Recurrent Malignant Glioma
  • Bevacizumab / Irinotecan
  • Functional MR Imaging
  • Metabolic Imaging (FET/FLT-PET)
  • Glioma

Name

Location